Skip to content

Preparation of Radiopharmaceuticals by Automaton: Operators Dosimetry

Evaluation of a New Strategy for the Preparation of Technetium Radioactive Medicaments Using an Innovative Automaton for Nuclear Medicine Examinations: Impact on the Dosimetry of Operators and on the Quality of Preparations

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03974256
Acronym
AUTOTEC
Enrollment
22
Registered
2019-06-04
Start date
2022-01-01
Completion date
2024-07-01
Last updated
2021-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exposure, Radiation

Keywords

Automaton, Dosimetry, Radiopharmaceutical, Technetium-99m

Brief summary

The radiopharmaceuticals manipulation used in nuclear medicine department is a significant source of radiation for operators. According to Article R. 4451-13 of the Labor Code, the exposure limit for hands and skin (average dose over a surface of 1 cm²) received during twelve consecutive months can't exceed the annual dose limit 500 millisieverts (mSv). The radiopharmaceuticals manipulation exposes operators to the risk of exceeding this limit, as has been shown in a European study. At present, there are automatons on the market but only for radiopharmaceutical fluorodeoxyglucose (FDG). One of the advantages of such an automaton is to reduce irradiation of operators' hands during the radiopharmaceuticals preparation. This reduction can reach 95% according to certain authors and the type of automaton. This study therefore proposes to evaluate the effect of an original, newly designed automaton on operators' dosimetry and the labelled radiopharmaceuticals' quality. The hypothesis emitted in this study is that the use of this automaton would allow to reduce drastically operators' hands exposure and probably also to improve the precision of the prepared syringes. This study will be done in a paired way, require a randomization in cross-over and each of the subjects included will be its own witness.

Detailed description

Currently, radiopharmaceuticals for diagnostic purposes are prepared by operators, Technologist in Medical Electro-Radiology or/and Pharmacy Technicians, manually for radiopharmaceuticals labelled with Technetium-99m (99mTc), or using an automaton for radiopharmaceuticals FDG. At present, there are automatons on the market but only for radiopharmaceuticals FDG. However, these automatons are currently only used to split into individual doses radiopharmaceuticals FDG, the labelling radiopharmaceuticals being carried out before delivery in nuclear medicine departments. The Sysark SAS's company has created and patented, with the collaboration of the Center of Research in Automatic Control of Nancy (CRAN, mixed unite of research 7039 common to the University of Lorraine and the CNRS) an innovative automaton for the preparation of radiopharmaceuticals labelled with 99mTc, used to perform scintigraphy examinations of nuclear medicine department.

Interventions

OTHERTraining in the use of the automaton

2 days training on automaton use

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Intervention model description

Interventional study, multicenter, randomized, cross-over, open, at risk and minimal constraints

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult (age \> 18 years) * Operators: Technologist in Electro-Radiology Medical / Pharmacy Technician * Operators experienced and autonomous in labelling radiopharmaceuticals with technetium-99m, at least one year * Operators having agreed to participate in the study, having received complete information on the organization of the research and having signed a free and informed consent * Operators affiliated to a social security scheme or beneficiary of such a scheme

Exclusion criteria

* A woman of childbearing age who doesn't have effective contraception * Persons referred in Articles L. 1121-5, L 1121-8 of the French Public Health Code: * Pregnant woman, parturient or mother who is breastfeeding * Chil (not emancipated) * Adult subject to a measure of legal protection (guardianship, curators, safeguard of justice) * Adult unable to express consent * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1

Design outcomes

Primary

MeasureTime frameDescription
Total radiopharmaceutical activity prepared in mega-becquerel (MBq)Throughout 4 working days of each methodsFor each of the two methods of preparation
Number of days of handlingThroughout 4 working days of each methodsFor each of the two methods of preparation

Secondary

MeasureTime frameDescription
Accuracy in terms of activity (MBq) of prepared syringes, expressed as a percentage (%) of the prescribed target value, and compared between the automated device and the conventional manual methodThroughout 4 working days of each methodsFor each of the two methods of preparation
A likert of 4 modalities will be used to evaluate the level of comfort in the automaton by operators (from Very uncomfortable to Very comfortable)After 4 working days of this methodDuring the automated method of preparation
A likert of 4 modalities will be used to evaluate the confidence level in the automaton by operators (from Not at all confident to Totally confident)After 4 working days of each methodsDuring the automated method of preparation
Level of operators' irradiation, measured by the breast dosimeter during the 4 days of preparation (in µSv) and expressed in relation to the total radiopharmaceuticals' activity prepared during the same period (in MBq)Throughout 4 working days of each methodsFor each of the two methods of preparations

Countries

France

Contacts

Primary ContactRachel GRIGNON, Technologist
r.grignon@chru-nancy.fr+33 383155423
Backup ContactVéronique ROCH, MSc
v.roch@chru-nancy.fr+33 383154276

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026